Bengaluru, July 16 -- The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company expanded its diabetes portfolio with the USFDA Approval.

With a market capitalization of Rs 52,950.44 crore, the shares of Biocon Ltd were trading at Rs 396.05 per share, increasing around 1.50 percent as compared to the previous closing price of Rs 390.20 apiece.

US FDA Approval The shares of Biocon Ltd have seen bullish movement after announcing that the U.S. Food and Drug Administration (FDA) has approved Kirsty, 100 units/mL, as the first and only interchangeable* biosimilar to NovoLog (Insulin Aspart).

Moreover, KIRSTY is a fast-acting human insulin analog designed to enhance glycemic contro...